Our team brings together proven leaders with diverse experiences and deep expertise across all aspects of a successful biotech company. We are united by a belief in the transformative potential of gene therapy and by our steadfast commitment to making a difference in the lives of children and families affected by rare disease.

member image alt text
Bobby Gaspar, M.D., Ph.D.
Chief Executive Officer
To me, leading Orchard is an opportunity to change medicine and change the lives of individuals with severe genetic diseases and their families. Through our hematopoietic stem cell platform, cutting-edge science and innovation, and well-executed clinical studies, we can deliver potentially curative therapies for patients. However, the success of our efforts also requires enabling meaningful access to therapy and building the necessary infrastructure across core pillars – regulatory science, manufacturing, diagnostic and commercial capabilities, and education and advocacy – to ultimately deliver on our mission to potentially transform lives.

Bobby is a world-renowned scientist and physician and accomplished strategic and organizational leader with more than 25 years of experience in medicine and biotechnology. As one of Orchard’s principal scientific founders, Bobby serves as chief executive officer of the company, and also sits on Orchard’s board of directors. Bobby has been a pioneer in gene therapy and the evolution of hematopoietic stem cell (HSC) technology – including some of the first studies in patients with severe combined immunodeficiency (SCID) – bringing it from some of the first studies in patients to potential regulatory approvals. His unparalleled expertise and deep relationships with key physicians and treatment centers around the world are integral to Orchard’s efforts to identify patients with metachromatic leukodystrophy (MLD) and other diseases through targeted disease education, early diagnosis and comprehensive newborn screening.

Bobby is a professor of pediatrics and immunology at the UCL Great Ormond Street Institute of Child Health and has led multiple clinical trials that have shown that gene therapy can successfully correct the genetic defect in immune deficiencies. He studied medicine and surgery at Kings College in London before completing his Ph.D. at the UCL Institute of Child Health.

member image alt text
John Cerio
SVP & Global Head of Human Resources
We are building a highly collaborative culture with a deep understanding and appreciation of our diverse talents and collective strengths, and an abiding commitment to our mission to potentially transform the lives of families affected by rare disease.

John brings over 25 years of human resource (HR) leadership experience in the pharmaceutical and biotech industry building high growth, high performance, mission-driven and entrepreneurial companies. Most recently, John served as vice president of human resources and administration for Agenus, where he led the HR function through periods of rapid growth, transformation and global expansion. John played a key role in leading the acquisition and integration of 4-antibody AG and the build-out of the company’s R&D and technical operations capabilities responsible for generating and advancing an immuno-oncology portfolio of over a dozen clinical candidates. Prior to Agenus, John was vice president of global HR for PerkinElmer Life Sciences, during which time the company more than doubled in size and annual sales and significantly expanded its commercial business and operations in the U.S., Europe and APAC regions. Earlier in his career, he spent nearly 10 years with Bristol-Myers Squibb in a series of progressively responsible HR leadership roles including director of HR for corporate staff, director of organizational development for U.S. medicines and head of HR for the oncology and immunology division.

John earned his B.S. in industrial and labor relations from Cornell and his M.A. in organizational psychology from Columbia with a concentration in organizational development. He also completed the global leadership development program at the London Business School.

member image alt text
Anne Dupraz-Poiseau, Ph.D.
Chief Regulatory Officer
We will always be confronted by obstacles in life. The important thing is being open to new routes to meet our goals and going beyond our limitations. This is what Orchard is working towards: developing the medicines of tomorrow, which might previously have been seen as impossible, but will potentially be standards of care in the future.

Anne has 25 years of experience tackling R&D, clinical and regulatory challenges for global development within medtech and biotech companies. Anne joined Orchard Therapeutics in 2016 to lead global regulatory strategy and devise innovative and expedited pathways for the development and the registration of Orchard’s HSC gene therapies. She built and manages an international, highly-trained and experienced regulatory team. Prior to joining Orchard Therapeutics, she was executive vice president at Voisin Consulting Life Sciences (VCLS), an international consulting firm highly experienced in orphan drug development. In her leadership role, Anne was actively involved in the design, preparation and management of a high number of successful regulatory submissions at all stages of product development. Anne had a pioneering role in the field of advanced therapies and managed over 50 different tissue, cell and gene-based therapy development programs. Over the years, Anne has established strong communication links with regulators, including the Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the European Member States’ medicine agencies. Bringing together scientific and regulatory expertise in the Advanced Therapies Medicinal Products (ATMPs) area, Anne actively participated in the elaboration of the European ATMP Regulation through industry associations and worked closely with the EMA on related guidelines. Before joining VCLS, Anne co-founded the regulatory consulting firm Meditest International. Anne began her career as a research & development project manager for Medtronic Sofamor-Danek.

Anne earned a joint Ph.D. in biomaterials and artificial organs from the University of Dental Surgery in Nantes, France, the Free University of Berlin, Germany, and the University of Medicine of Leiden, Netherlands, working on the development and evaluation of drug-device combination products aimed at bone substitution.

member image alt text
Adrien Lemoine
Chief Business Officer
Orchard’s technology and industry-leading pipeline of potentially curative gene therapies offers the opportunity to transform the lives of patients while potentially revolutionizing medicine.

Adrien brings nearly 20 years of experience creating value for pharma and biotech companies. His responsibilities at Orchard Therapeutics include overseeing business development, program management, program leadership and portfolio strategy for the company. Since joining Orchard in October 2016, he has led the build-out of Orchard’s industry-leading gene therapy pipeline through multiple in-licensing deals, notably the acquisition of GSK’s gene therapy portfolio in April 2018. Prior to joining Orchard, Adrien was executive director, corporate strategy and development at AstraZeneca where he led M&A activities as well as successful out-licensing, divestments and new company spinoff projects. He also served as a member of Corvidia Therapeutics’ board of directors. Prior to AstraZeneca, Adrien spent nine years at GSK; his most recent role was strategy & operations director in the rare disease unit, working in particular on GSK’s ex vivo autologous HSC gene therapy portfolio. He was a member of the advisory committee for Kurma BioFund II, a venture capital fund with a special focus on rare diseases. His experience at GSK also encompasses European and global roles of increasing seniority in R&D portfolio strategy and commercial analysis. He started his career as a strategy consultant at Alcimed in Paris, France, supporting the development of biotechnology startup companies. 

Adrien holds an engineering degree from Supélec in Paris and a M.Sc. in engineering and physical science in medicine from Imperial College in London.

member image alt text
Andrea Spezzi, M.D.
Chief Medical Officer
From my days as a pediatrician, helping children with severe diseases has been my life’s purpose. Delivering potentially transformative products would be the culmination of many years of collective work and our mission to give back to families, science and society as a whole.

Andrea brings extensive experience and expertise in the development and execution of all aspects of clinical development, particularly in pediatric rare diseases. Prior to co-founding Orchard Therapeutics, Andrea served as vice president and medicine development leader at the GSK rare diseases unit, and before that as senior medical director at the immune inflammation discovery performance unit. Before GSK, Andrea was global medical director R&D at Takeda in the metabolic and cardiovascular area and in charge of the pediatric developments for Takeda Europe R&D. She previously worked as a research physician at Hammersmith Medicines Research. Before moving to the pharmaceutical industry, Andrea practiced as a pediatrician for 12 years in Argentina, Spain, and the UK. Andrea was recognized as one of 2018’s “Fiercest Women in Life Sciences” by FiercePharma and as one of BioBeat’s “50 Movers & Shakers in BioBusiness” in 2017. 

Andrea obtained her medical degree from the University of Buenos Aires (UBA) and completed residency in pediatrics and postgraduate training in pediatric immunology at the Dr. Elizalde Children’s Hospital in Buenos Aires, Argentina. Andrea also obtained a specialist in pharmaceutical medicine degree from University of Basel, Switzerland. She is a fellow of the Faculty of Pharmaceutical Medicine (FFPM) in London.

member image alt text
Frank Thomas
President & Chief Operating Officer
As a leader in gene therapy, I believe we should be providing innovative solutions across the continuum of a fully integrated company, all while turning groundbreaking innovation into transformative therapies for patients, supporting revolutionary ways to improve access to treatment, and driving long-term growth and value.

Frank brings nearly 20 years of experience in the biopharmaceutical industry as an accomplished financial and business executive, with a proven track record of success in leading operations and strategy, corporate finance and commercialization at publicly traded biotechnology companies. Frank joined Orchard in 2018 as chief financial officer. Since that time, his role has expanded to president and chief operating officer of Orchard. In this capacity, Frank creates and drives strategies for overall value-creation and long-term growth of the company. He currently oversees key functional areas for the business, including but not limited to, finance, commercial operations, corporate affairs and quality.

Frank previously served as president and chief operating officer of AMAG Pharmaceuticals, where he helped develop the business from a single product company in 2011 to one with a portfolio of commercial and development-stage products that generated more than $600 million in sales in 2017. During that time, Frank raised more than $1.8 billion in new capital to support AMAG’s growth strategy. Before joining AMAG, he served as chief operating officer and chief financial officer for Molecular Biometrics, Inc. Earlier in his career, Frank also served as chief executive officer for Critical Therapeutics and chief financial officer for Esperion Therapeutics. Each company completed its initial public offering in the U.S. during his tenure. Frank currently serves on the board of directors of Zafgen and Spero Therapeutics.

Frank received his B.B.A. in business administration from the University of Michigan, Ann Arbor.

Board of Directors
Steven Altschuler, M.D.

Steven brings nearly 20 years of experience building and leading world-class, integrated, translational, value-based health care systems and transformational biotechnology companies. He currently serves as managing director of Healthcare Ventures at Ziff Capital Partners and was previously chair of the board of directors at Spark Therapeutics (now part of Roche) for six years, from its founding until it was acquired in 2019. In his role at Ziff Capital Partners, Dr. Altschuler co-leads the firm’s efforts toward investing in, and facilitating the start-up and development of, companies with potentially transformative technologies that emphasize cellular and molecular approaches to human disease. He previously co-founded Spark Therapeutics to develop and commercialize the preclinical and clinical gene therapy programs advanced at the Children’s Hospital of Philadelphia (CHOP) and other institutions. He served as Spark’s board chair from its founding through its acquisition in 2019, which included leading the company through a successful transition to a public company and the launch of an approved commercial product, which was the first gene therapy for an inherited disease approved by the U.S. Food and Drug Administration and European Medicines Agency. Dr. Altschuler formerly held chief executive positions at CHOP and University of Miami Health System. He is chairman of the board of directors of 89bio and a member of the board of directors of WW (formerly Weight Watchers International), AsclepiX Therapeutics, ImVaX and Platelet Biogenesis. He is also an independent trustee of the Brigham and Women’s Physician Organization at Mass General Brigham.

Dr. Altschuler holds a B.A. in mathematics and an M.D. from Case Western Reserve University.

Title of the wysi

The site uses cookies to provide you with a more responsive and personalized service. By using this site, you agree to our use of cookies as set out in our cookie policy.

Please read our privacy policy and cookie policy for more information on the cookies we use and how to delete or block the use of cookies.